As the development of fibrosis in NAFLD has been associated with increasing plasma AST and AST/ALT ratio, we also assessed if selecting patients by these would be helpful for targeting screening. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.